NightingaleFor Biopharma
For clinical operations & data managementLive at Emory University

Clean trial data from the first visit. Without changing your sites.

Nightingale takes in everything your trial produces, checks it against the protocol and the regulators' rules, and delivers it into your EDC in exactly the form you specify, with a complete audit trail, for the whole trial. Every week saved is a week sooner that a treatment reaches the patients waiting for it.

8.1 daysvisit to EDC today
~97Kqueries per Phase III
$556Kcost per day of delay
≤ 5%of trial budget
GxPaudit complete
01 · The problem

Your trial data is typed in by hand, and cleaned up months later.

Many documents, many owners, and nobody reconciling them. Every disagreement becomes a query, and every day of cleanup delays lock.

SponsorProtocolWhat is measured, when, in what units
Sponsor / CROEDC buildAccepts values the protocol forbids
Each labLab manualsFive labs, five sets of units
Sponsor / IRBPharmacy, consent, questionnairesDrift through amendments
Each siteSource systems40 sites = 40 different setups
58%changed nothing
~97,000

queries per Phase III study. Most confirm correct data was correct. 6

Cost of one day of delay 7
$556K / day
$55,716 direct~$500,000 forgone revenue

What a delay costs over the life of a trial

90
3
Direct cost of the delay
$5.0M

$55,716 per day: staff, sites, vendors kept running 7

Forgone revenue
$45M

~$500,000 per day a marketable treatment is not on sale 7

Manual data-management labor
$655K

Five-person team, ~12 hrs/week each on queries and reconciliation, $70/hr 89

02 · What Nightingale does

One layer from every source to your EDC.

One piece of software between every data source and your EDC, running for the whole trial. Your sites are never asked to do anything new.

WHAT GOES INNIGHTINGALE · RUNS FOR THE WHOLE TRIALWHAT COMES OUT The study's rulebook Protocol · endpoints Lab & pharmacy manuals Consent · questionnaires Data-entry guide · output spec The regulators' rulebook FDA guidance · Part 11 EMA (EU) · ICH E6(R3) The data · each site's own Hospital records (EHR) Labs · imaging · pharmacy Wearables · devices · apps Telehealth visits Handwritten notes · paper Real-world evidence 1 · Check the rulebook Study documents vs each other vs FDA / EMA / ICH → every conflict flagged 2 · Inventory What already exists, incl. real-world evidence 3 · Find the gap Your required output vs what exists → what to collect 4 · Run the data · fixed rules map field → convert unit → check range → deliver Same input always gives the same output. No retyping. AI reads documents; fixed rules decide. 5 · Watch it daily Gap re-checked on live data. Advance notice if an endpoint is at risk. 6 · Prove every step Audit trail per data point: created, verified, or fixed & flagged. ↻ steps 4-6 repeat every day until the last data point 7 · Close and submit Endpoints met? If not, why, and what to enroll. Submission-ready package for the regulator. 8 · Every trial feeds the cross-trial data layer Consented, de-identified, identically structured. The basis for Layer 3. Your EDCMedidata · Veeva · Oracle · any Your output formatExactly as specified Audit recordEvery value, every step RegulatorReal-time feed · submission package Storage stays with you. Layer 3 · synthetic control arms · digital twins · cross-trial discovery · new treatments
Hover a stage to trace its inputs and outputs; click to see an example. Every stage produces something you can open and check.
1

Check the rulebook

Every study document vs each other and vs FDA, EMA, ICH. Conflicts flagged before enrollment.

ExampleProtocol in kilometers, lab manual in miles. Flagged on day one, not month four.
2

Inventory what exists

Records, prior labs, device history and paper, filtered to what counts.

ExampleTwo years of blood pressure already in the chart get structured and counted.
3

Find the gap

What you need minus what exists = what to collect.

ExampleECGs needed at weeks 4, 12, 24; records cover week 4 for a third of patients.
4

Run the data

Map, convert, check, deliver into the EDC. No retyping.

ExampleWatch reports 10 miles; 16.09 km lands in the right field, with the conversion recorded.
5

Watch it daily

Gap re-checked on live data; early warning when an endpoint is at risk.

ExampleSite 17's ECG timestamps drift 40 minutes. Flagged in week 3, not at lock.
6

Prove every step

An audit trail for every data point, created or verified.

ExampleWhere did this glucose value come from? One click: device, time, conversion, reviewer.
◉AI readsDocuments, notes, scans, photos
▣Rules decideFixed rules you can read. No AI in the pipeline.
✕ Not a database✕ Not a CRO✕ Not a tool for sites✕ Not a regulated device

A source link proves a number is real. It does not prove it is right. Every value carries two things: where it came from, and the rule that produced it, checked against the protocol, the lab manual and the consent form before the first patient. When one of those documents changes, the values it governs are flagged for re-review rather than quietly inheriting the old definition.

03 · Across your trial

What happens at every stage of your study.

Nightingale runs from before the first patient is enrolled until your data is ready for the regulator.

Before enrollmentCheck the rulebook
  • Protocol, lab and pharmacy manuals, consent and eCRF guidelines reconciled
  • Conflicts flagged on day one, not month four
Study start-upInventory & gap
  • Existing records structured as real-world evidence
  • What your endpoints still need, defined up front
During the trialRun, watch, prove
  • Every source into your EDC in minutes
  • Gap re-checked daily on live data
  • Audit trail on every value
Close-outLock sooner
  • Endpoints met? If not, why
  • Submission-ready package
  • ~10 days of cleanup instead of ~90 in the illustrative Phase III

Early warnings you would otherwise miss

Week 3

One site's ECG device timestamps drift from its visit log. Fixed before it becomes a protocol deviation.

Month 8

Enrollment at four sites is on pace to miss a secondary endpoint. You re-allocate before it costs a quarter.

Any day

A lab slip arrives as a photo; the protocol wants a table. It is read, structured and checked against the range.

At close

Every value traces to its source device, time, conversion and reviewer, in one click.

Examples describe what the monitoring stages are built to surface, not results from a specific study.

04 · For your teams

What each of your teams gets.

Select a team to see what changes for them.

What changes for you
Fewer surprises, and no new burden on your sites.
8.1 days → minutesvisit to EDC
0new site logins
What you get
  • Sites never asked to do anything new; re-keying goes down
  • Daily early warnings on sites and endpoints at risk
  • Advance notice while there is still time to act
What changes for you
Clean data as it arrives, not at lock.
~60K vs ~150Kqueries, illustrative Phase III
~10 vs 90days of cleanup
What you get
  • Units converted and ranges checked before data reaches the EDC
  • Design-origin queries never created
  • Every source connected once, delivered in your format
What changes for you
A submission-ready record, built as the trial runs.
100%of values traceable
E6(R3)aligned
What you get
  • Audit trail on every value: source, time, conversion, reviewer
  • The record of where each value came from and how data moves, produced automatically
  • Output in the standard submission format, with a clear trail behind anything AI touched
What changes for you
A vendor that passes qualification, and stores nothing.
GxPaudit complete
0copies of your data stored
What you get
  • GxP vendor audit complete; Part 11 aligned; SOC 2 Type II in progress
  • Storage stays with you; your EDC is the system of record
  • Fixed, written-down rules; no AI in the data path
What changes for you
A reproducible quote that stays inside the tech budget.
≤ 5%of trial budget
up to 10%portfolio discount
What you get
  • Priced on patients, sources, phase and duration
  • Capped at 5% of the trial budget
  • Volume discount up to 10% for committed portfolios
05 · Why now

Regulators now expect continuous, traceable data.

On 28 April 2026 the FDA launched Real-Time Clinical Trials, and ICH E6(R3) requires you to prove where every value came from.

3.6M
data points per Phase III protocol, 3× a decade ago 1
+34% / yr
growth in connected devices in trials 2
8.1 days
from patient visit to your database 3
8.23%
error rate when records are re-keyed by hand 5
Dec 2023FDA digital health guidanceFirst system data lands in is the official source
Sep 2025ICH E6(R3) in forceProve where every value came from
Jan 2026FDA + EMA AI principlesAI needs data you can trace back
Apr 2026Real-Time Clinical TrialsContinuous data to the regulator
Sep 2026ARPA-H SURPASSFederal funding for real-time, adaptive trials
Jan 2027E6(R3) Annex 2Same rules for decentralized trials and RWE
06 · Trials in scope

How many trials this applies to.

How many studies a year this applies to, counted from the public registry rather than estimated from market reports.

35,000+
new studies registered every year 13
~20,000
interventional trials a year we can serve, our estimate 13
~28.5%
of interventional trials are industry-sponsored; the rest are academic, hospital or government 21
Every phase
Phase I to IV, plus device, diagnostic and software studies
In scope

Interventional trials of any phase, and device, diagnostic or digital-health studies, that collect data from more than one electronic source and report into a study database.

Best fit today

Studies with wearables, home visits, several labs or many sites, where reconciling sources by hand is the bottleneck.

Out of scope

Registry-only and observational studies with a single data source, where there is little to reconcile.

The trial pool keeps growing: registrations have risen every year since the registry opened in 2000 13. Counts are from public registry data; the in-scope figure is our estimate, not a registry statistic.

07 · Your return

A large Phase III, run both ways.

Without Nightingale
With Nightingale
Sources to reconcile
14 sources · 120 site setupsfive lab manuals, by hand
14 sources · connected onceall manuals reconciled on day one
Visit → data in database
8.1 daysre-keyed by coordinators
Minutesautomated, no retyping
Queries over the trial
~150,00058% change nothing
~60,000queries from conflicting study documents never happen
Errors from re-keying
~250,000 values8.23% of ~3M hand-entered fields
~0 · source errors flaggedevery value carries its origin
Cleanup before database lock
90 daystypical for a trial this size
~10 daysdata was clean as it arrived
Data-management labor
$1.3Mten-person team, three years
$0.4M70% of manual work removed
Cost of the lock delay
$50M$5M direct + $45M forgone revenue
$5.6M80 days recovered
Audit trail at submission
Partialreconstructed after the fact
Completeevery value, every step, E6(R3)-ready
Without
36 months of trial+3 mo to lock
With
36 months of trial~80 days to market sooner
~$45M
saved or recovered on one trial
~$3.3M
Nightingale contract, 2.6% of budget
$14 : $1
back per dollar spent

Illustrative: 2,000 patients, 120 sites, 14 sources, three years, scaled from published per-study figures. Design targets under validation, not measured averages.

08 · Pricing

Priced on the work in your study.

Quotes are reproducible from the same four inputs every time: patients, data sources, phase and duration. Price your study in the calculator below.

Price your trial

1,650
3001,6503,000
6
3
1
150
Volume discount0%
TierSingle trial
Saved per trial$0
Portfolio saving$0

Discount grows with each doubling of trials committed, capped at 10%.

Nightingale · per trial
·

Share of trial budget·
Share of the ~10% technology budget·
Portfolio total (1 trial)·
What you get back
·

Total benefit over the trial

Days saved on the trial·
Manual data handling removed·
Delay avoided, direct cost (30 days)·
Earlier revenue (marketable treatment)·
Return
·

for every dollar spent on Nightingale

Estimated trial budget·
Technology budget (~10%)·
Your net gain·

Budget from ~$41,000 per patient 10; savings from a data-management team scaled to enrollment 89 and delay days at $55,716 direct and ~$500,000 forgone revenue per day 7, counted in full only for studies that lead to market (15% at Phase I, 35% at Phase II). Days saved is an output, not an input: 14 days of head start before the first patient, plus up to 49 days of cleanup slip avoided, 8 days per connected eSource.

Your second trial costs less effort than your first

Your first trial
Deployment~4 weeks
Security & vendor reviewsCarried once
IntegrationOne-time
Volume discount0%
Every trial after
Deployment~2 weeks
Security & vendor reviewsSkipped
IntegrationStarts from existing connectors
Volume discountGrows to 10%
09 · Compliance & security

Built for a vendor-qualification review.

CompleteGxP vendor audit

The standard regulated life-science vendors are held to.

Aligned21 CFR Part 11

The FDA rule for electronic records.

AlignedICH E6(R3)

A record behind every value, from source to submission.

In progressSOC 2 Type II

Independent security audit underway.

By designStorage stays with you

Not a database. Your EDC remains the system of record.

By designNo AI deciding your data

Fixed rules; the same input always gives the same result.

OutputStandard format

Delivered in exactly the format you specify.

Any EDCMedidata · Veeva · Oracle

Neutral to whichever database the study runs.

What your quality team receives

Audit trail per value

Created if missing, verified if present, and anything wrong flagged.

Data-flow diagram

The E6(R3) diagram of how data moves, produced from the running pipeline.

Documented, validated systems

The rulebook model and pipeline are documented as validated systems.

10 · How to engage

Directly, or through your CRO.

Direct

Work with Nightingale

  • A 30-minute portfolio review of your active trials
  • A complimentary data flow review of one study
  • A written, reproducible quote
  • A parallel run on one study before you commit
Through your CRO

Ask your CRO for it

  • Our CRO partners deliver Nightingale under their own brand
  • Same pipeline, audit trail and compliance posture
  • Your CRO owns the relationship and the pricing
How we startFour steps, proven on your study.
Step 01Portfolio Review

A 30-minute call on your active trials and where data work is costing you today.

Step 02Data Flow Review

A complimentary hands-on review of one active trial: sources, cleanup steps, and EDC targets.

Step 03Scope and Quote

Written findings and a quote reproducible from patients, sources, phase and duration.

Step 04Parallel Run

Baseline a comparable trial, run Nightingale alongside on one study, then compare the number of queries, how many are resolved first time, and the lock date.

11 · Where we are today

Live on real patient data.

Flagship deployment

EmpowerMBC at Emory University, a Gilead-funded oncology study under Dr. Lauren McCullough, is our live deployment and the reference we will put on a call. We will baseline on your study before we claim anything.

Traction

$340K contracted across signed agreements: Emory University plus two medical-device trials via Thinq CRO. Harvard iLab company, 11 signed channel partners, and onboarding into the Georgia CTSA Program.

12 · FAQ

The questions biopharma teams ask.

Tap a question for the full answer.
In shortWe feed your EDC; we do not replace it.
In shortNothing new for your sites.
In shortThe gate a qualification team applies is already behind us.
In shortYour data stays in your systems, under terms in the contract.
In shortAI reads; rules decide.
In shortSource links show where a value came from. We show what it means, and tell you when that changes.
In shortExisting records count, once they are structured.
In shortOne study, measured, before any portfolio decision.
13 · Get in touch

Start with a portfolio review.

Thirty minutes on your active trials and where data work is costing you today.

Yash Vagal
Co-Founder and CEO, Nightingale

Pick a time that works for you. We will walk through your trials and where Nightingale would make the biggest difference.

30-minute callVideo call
Book a portfolio review

What happens next

1Portfolio review

A 30-minute call on your active trials.

2Data flow review

A complimentary hands-on review of one active trial.

3Scope and quote

Written findings and a reproducible quote.

14 · Appendix · sources

Sources behind every figure.

Show all 20 sources
  1. Tufts Center for the Study of Drug Development (2021): Phase III protocols average 3.6 million data points, three times the volume of ten years earlier.
  2. Marra C. et al. (2020), npj Digital Medicine: connected digital products in trials grew ~34% per year, 2000-2017.
  3. Tufts CSDD, eClinical Landscape Study: 257 organizations; median 8.1 days from patient visit to EDC entry.
  4. Advarra, Study Activation Survey 2023: N>500 sites; ~69% use six or more sponsor systems.
  5. Garza M. et al. (2026): manual transcription error rate 8.23%; integrated capture showed no detected transcription errors.
  6. Stokman P. et al. (2021), Journal of the Society for Clinical Data Management 1(1), DOI 10.47912/jscdm.20: 20 Phase III studies, 1,939,606 queries; ~96,980 per study; 42% resulted in a data change.
  7. Smith Z., DiMasi J., Getz K. (2024), Therapeutic Innovation & Regulatory Science 58(5):855-862: direct cost of trial delay $55,716/day; opportunity cost on the order of $500,000/day.
  8. Salary.com, US Clinical Data Manager compensation, September 2026: average $144,625, ~$70/hour.
  9. Vendor-sponsored industry survey, n=88: ~12 hours/week per data manager per study on query and reconciliation work. Indicative.
  10. Moore T. et al. (2018), JAMA Internal Medicine: median cost per patient in pivotal trials ~$41,117. Per-source and fixed-cost components are estimates.
  11. IQVIA Institute, Global Use of Medicines: global medicine spending ~$1.6T. Medical device market ~$600B (industry estimate). WHO: global health spending ~$10T.
  12. Evaluate Pharma / IFPMA: pharmaceutical R&D ~$300B per year; medtech and digital-health R&D ~$50B (estimate). IQVIA Technologies, Veeva and Medidata combined revenue ~$10B.
  13. ClinicalTrials.gov: more than 35,000 new studies registered per year. The ~20,000 addressable interventional figure is an estimate.
  14. ClinicalTrials.gov sponsor records: Pfizer ~423 tracked / 251 active; Eli Lilly ~333. Order-of-magnitude proxy.
  15. ICH E6(R3): §3.16.1(c), §3.16.2(c), §2.12. Step 4 6 Jan 2025; EU 23 Jul 2025; FDA 9 Sep 2025; Annex 2 adopted 3 Jun 2026, effective 15 Jan 2027.
  16. FDA Digital Health Technologies guidance (Dec 2023); FDA Part 11 Q&A (Oct 2024); FDA and EMA AI principles (Jan 2026); FDA Real-Time Clinical Trials (28 Apr 2026); HHS and ARPA-H SURPASS (Simulation-augmented, Real-time Platform Adaptive Seamless Trials), solicitation ARPA-H-SOL-26-164 (30 Sep 2026).
  17. Disclosed transactions: Change Healthcare/Optum $13B; Datavant/Ciox ~$7B; Komodo Health $3.3B; Flatiron Health/Roche $1.9B; Truveta >$1B; Tempus AI market capitalization ~$10.6B.
  18. Public revenue multiples: Snowflake at IPO >100× trailing; Palantir ~80× (2025); Cloudflare ~35× (2025); Databricks ~27× (private, 2025).
  19. Private comparables: a September 2026 software seed round at $7M on $100M post-money with ~$500K lifetime revenue; a clinical-trial software company that raised under $400K in total and sold for roughly half a billion dollars. Details available on request.
  20. FDA, Considerations for the Design and Conduct of Externally Controlled Trials, draft guidance, February 2023. EMA, qualification opinion on prognostic covariate adjustment using digital twins (PROCOVA), September 2022.
  21. Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019, JAMA Network Open (2020): of 245,999 interventional studies, 70,329 (28.5%) were industry-sponsored.